GlassScriptPhysician profile
David L Burns
NPI 1548265481
$8,631.58
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,224 · 2020: $653 · 2021: $1,456 · 2022: $2,952 · 2023: $2,318 · 2024: $28.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,346.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,500.01 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $992.31 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $600.12 | 2020-2023 | Xifaxan, Trulance |
| Abbott Laboratories | $440.23 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $357.53 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $328.70 | 2022-2023 | Xarelto |
| Glaxosmithkline, LLC. | $328.25 | 2022-2023 | Trelegy Ellipta |
| Allergan, INC. | $301.71 | 2019-2020 | |
| Lilly USA, LLC | $297.99 | 2019-2023 | Mounjaro |
| Arbor Pharmaceuticals, INC. | $282.39 | 2019-2021 | |
| Amarin Pharma, INC. | $268.99 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $249.59 | 2022-2023 | Xarelto |
| Grifols USA, LLC | $224.23 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $211.24 | 2019-2023 | Farxiga, Breztri |
| Almirall LLC | $174.09 | 2022-2023 | Klisyri |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.